Lexeo Therapeutics (LXEO) Capital Leases (2022 - 2026)

Lexeo Therapeutics has disclosed Capital Leases across 5 years of filings, most recently posting $198000.0 for Q1 2026.

• Capital Leases for Q1 2026 came in at $198000.0, down 71.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $198000.0 (down 71.63% YoY), and the FY2025 annual result was $327000.0, down 59.98% from the prior year.
• Capital Leases came in at $198000.0 for Q1 2026 at Lexeo Therapeutics, down from $327000.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $1.6 million in Q4 2022 to a low of $198000.0 in Q1 2026.
• The 5-year median for Capital Leases is $873500.0 (2024), against an average of $870333.3.
• Across the five-year window, Capital Leases retreated 24.33% in 2023 and slumped 71.63% in 2026, its largest moves.
• Lexeo Therapeutics' Capital Leases stood at $1.6 million in 2022, then decreased by 24.33% to $1.2 million in 2023, then plunged by 34.48% to $817000.0 in 2024, then plunged by 59.98% to $327000.0 in 2025, then slumped by 39.45% to $198000.0 in 2026.
• The last three Capital Leases figures came in at $198000.0 (Q1 2026), $327000.0 (Q4 2025), and $454000.0 (Q3 2025), per Business Quant data.